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demonstrated evidence for decreased GL-3, although this clear-Globotriaosylceramide accumulation in the Fabry kidney is
ance was more limited than that observed in other cell types.cleared from multiple cell types after enzyme replacement therapy.
No evidence of immune complex disease was found by immuno-Background. Fabry disease, a lysosomal storage disease caused
fluorescence despite circulating anti-r-hGalA IgG antibodies.by deficient lysosomal -galactosidase A activity, is character-
Conclusions. These findings indicate a striking reversal ofized by globotriaosylceramide (GL-3) accumulation in multiple
renal glycosphingolipid accumulation in the vasculature and incell types, particularly the vasculature, leading to end organ
other renal cell types, and suggest that long-term treatmentfailure. Accumulation in the kidney is responsible for progres-
with r-hGalA may halt the progression of pathology andsive decline in renal function in male patients with the classical
prevent renal failure in patients with Fabry disease.phenotype, resulting in renal failure in their third to fifth de-
cades of life. With the advent of recombinant protein synthesis
technology, enzyme replacement therapy has become a viable
alternative to dialysis or renal transplantation, previously the Fabry disease is an X-linked recessive disorder in whichonly available treatment options for end-stage renal disease.
affected males are deficient in the lysosomal enzymeMethods. The pre- and post-treatment renal biopsies were
-galactosidase A. This deficiency leads to accumulationanalyzed from fifty-eight Fabry patients enrolled in a Phase 3
double-blind, randomized, placebo-controlled trial followed by of neutral glycosphingolipids, mainly globotriaosylcera-
a six-month open label extension study of the recombinant hu- mide (GL-3, also referred to as Gb3, ceramide trihexo-
man enzyme, -galactosidase A (r-hGalA), administered IV side, CTH), in tissues throughout the body. Progressive
at 1 mg/kg biweekly. The purpose of this investigation was to
glycosphingolipid accumulation results in clinical dis-detail the pathologic changes in glycosphingolipid distribution
ease, primarily in affected males, but some female het-and the pattern of post-treatment clearance in the kidney.
erozygotes may be symptomatic depending on the pat-Results. Baseline evaluations revealed GL-3 accumulations
in nearly all renal cell types including vascular endothelial cells, tern of Lyonization [1–3]. In affected males with the
vascular smooth muscle cells, mesangial cells and interstitial classical phenotype who have absent or very low levels
cells, with particularly dense accumulations in podocytes and of -galactosidase A activity, angiokeratomas, hypohi-distal tubular epithelial cells. After 11 months of r-hGalA treat-
drosis, acroparesthesias, transient ischemic attacks andment there was complete clearance of glycolipid from the endo-
stroke, congestive heart failure, cardiac conduction ab-thelium of all vasculature as well as from the mesangial cells of
the glomerulus and interstitial cells of the cortex. Moderate normalities, myocardial infarction, and progressive renal
clearance was noted from the smooth muscle cells of arterioles failure are the major clinical manifestations of the dis-
and small arteries. Podocytes and distal tubular epithelium also ease [4]. Atypical variants with residual -galactosidase
A have a milder phenotype with manifestations limited
to the heart (that is, the cardiac variant [5, 6]). Of note,1 Dr. Rennke, Dr. Colvin, and Dr. Dikman contributed equally to this
study. most cardiac variants do not have endothelial glyco-
sphingolipid deposition, do not develop renal failure andKey words: renal disease, Fabry disease, X-linked recessive disorder,
live a normal lifespan, but usually die of the late cardiacneutral glycosphingolipids, renoprotection, end-stage renal disease,
Phase 3 trial. manifestations of the disease. In contrast, progressive
renal failure in affected males with the “classic” form ofReceived for publication March 22, 2002
Fabry disease limits their average lifespan to the earlyand in revised form June 24, 2002
Accepted for publication July 22, 2002 forties, in the absence of dialysis or renal transplantation
[7, 8]. Until the recent advent of recombinant enzyme 2002 by the International Society of Nephrology
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replacement therapy [9], little could be done to combat in the kidneys of these Fabry patients and document-
ing the response of the various cell and tissue types tothe underlying pathology of Fabry disease, particularly
the progressive renal disease and vascular pathology re- r-hGalA treatment. Although a number of case reports
have described the main morphologic characteristics ofsponsible for the early demise of most patients. Recently,
a Phase 1/2 trial [9] and a Phase 3 trial with an open la- renal pathology and glycolipid accumulation in renal tis-
sue from Fabry patients [2, 19], little information is avail-bel extension [10] were conducted to evaluate the safety
and efficacy of recombinant human -galactosidase A able on the patterns of pathology among a larger group
of patients and the response of the cell types containing(r-hGalA) replacement therapy. These trials demon-
strated that r-hGalA replacement completely cleared GL-3 to recombinant enzyme therapy. Here, based on
a comprehensive analysis of the relevant renal cell types,GL-3 inclusions from the renal peritubular (interstitial)
capillary endothelium (the primary endpoint of the Phase we report on the clearance characteristics of each cell
type in response to r-hGalA (1 mg/kg biweekly). The3 trial) and effected equally remarkable clearance from
the capillary endothelium of other key tissues (heart, pattern of response in the different renal cell types pro-
vides insight into treatment strategies that are likely toskin and liver). Clearance of GL-3 from the plasma, uri-
nary sediment and homogenized kidney tissue also was succeed in improving the overall health of the kidney.
The findings are encouraging for the long-term benefitsdemonstrated. The identity of GL-3 and its clearance
from these samples were demonstrated by light micro- of r-hGalA replacement therapy in patients with Fabry
disease.scopic, immunohistochemical and biochemical analyses
[9, 10]. The endothelial end points for these Fabry trials
were chosen based on evidence implicating underlying
METHODS
vascular injury as the primary cause of the secondary
Patients and study designkidney pathology such as global glomerulosclerosis and
interstitial fibrosis [11, 12]. The study population comprised 58 Fabry patients (56
males, 2 females) enrolled in a five-month Phase 3, dou-Vascular injury has been implicated in organ damage
to the skin, heart, liver and CNS [4, 13]. The vascular ble-blind, randomized, placebo-controlled trial (29 pa-
tients in the treatment and placebo arms, mean age endothelium plays an important normal physiologic role
in glomerular perfusion, filtration, and maintenance of SD, 28.4  11.4 and 32.0  9.4 years, respectively). This
was followed by an additional six-month open label ex-a continuous anti-coagulant vascular lining. Injury to
endothelial cells in other disease settings leads to vaso- tension study, in which all 58 patients received enzyme
replacement therapy. Entry criteria required that patientsconstriction within the glomerulus, and intravascular in-
flammation and thrombosis of vessels in the renal cortex be 16 years of age or greater, with native plasma -galac-
tosidase A levels less than 1.5 ng/mL, and baseline serumand medulla, causing renal injury and failure [14–17] as
well as complications such as accelerated atherosclerosis creatinine levels less than or equal to 2.2 mg/dL. Recom-
binant-galactosidase A (r-hGalA; agalsidase beta; Fa-and thromboembolism [18]. More recently, investigators
have surveyed Fabry patients and confirmed the eleva- brazyme; Genzyme, Cambridge, MA, USA) at a dose of
1 mg per kilogram of body weight or placebo (phosphate-tion of markers of endothelial cell injury and activation
[intracellular adhesion molecule-1 (ICAM-1), vascular buffered mannitol) was administered intravenously at a
rate of 0.25 mg per minute, every two weeks. Completecell adhesion molecule-1 (VCAM-1), P-selectin], leuko-
cyte activation (CD11b) and coagulation [tissue plas- sets of three diagnostic quality renal biopsies taken per
protocol at baseline, five months and 11 months, wereminogen activator (tPA), von Willebrand factor (vWF),
plasminogen activator inhibitor (PAI)] [11, 13]. These available for 48 of the 58 patients. The remaining ten
patient sample sets were available but were limited toabnormalities suggest that the vascular endothelial cells
of Fabry patients are in a chronic pro-inflammatory and one or two of the three time points.
pro-thrombotic state [11, 13]. Loss of nephrons from vas-
Light microscopycular injury leads to increased pressures on remaining
nephrons, leading to further accelerated nephron injury. Preliminary studies revealed that the lipid was best
demonstrated for light microscopy in one-micron, eponClearance of GL-3 from the endothelium by r-hGalA,
therefore, is expected to alleviate ongoing vascular dam- embedded sections. Therefore, renal biopsies were fixed
in 3% glutaraldehyde in 0.2 mol/L sodium cacodylateage and prevent progressive perfusion deficits that would
otherwise contribute to renal failure in these patients. buffer, pH 7.3, followed by post-fixation in 1% osmium
tetroxide in 0.2 mol/L sodium cacodylate (Electron Mi-The primary emphasis of the Phase 3 clinical trial was
on establishing the significance of the vascular endothe- croscopy Sciences, Fort Washington, PA, USA). The tis-
sue was infiltrated overnight, and then embedded in alial endpoints and monitoring numerous clinical and safety
parameters [10]. A substantial effort also focused on char- 1:1 mixture of Epon 811 A and B (Electron Microscopy
Sciences), plus DMP-30/Propylene Oxide (Electron Mi-acterizing the pathologic patterns of GL-3 accumulation
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Table 1. Scoring system for GL-3 accumulation/clearancecroscopy Sciences). One micron sections were stained
in different renal cell types
with a 1:1 mixture of Methylene Blue in 1% sodium bor-
Cell/tissue Scoreate and 1% Azure II (Fisher Scientific, Fairlawn, NJ, USA).
Glomerular endothelial cells 0  None or trace accumulation
Peritubular capillary endothelial 1  Mild accumulationScoring of light microscopy
cells 2  Moderate accumulation
Each renal biopsy was reviewed under light micros- Arterial/arteriolar endothelial 3  Severe accumulation
cellscopy by three independent renal pathologists who were
Vascular smooth muscle cells
blinded to treatment status of the patient at the time of Podocytesa
DCT/collecting ductsabiopsy. All pathologists participated in preliminary ses-
Mesangial cells: GL-3 0  No lipid granulessions to establish the criteria for the grading scale used
accumulation 1  Minimal lipid granulesto evaluate baseline GL-3 content and subsequent clear-
Interstitial cells 2  Numerous lipid granules
ance from affected tissues. Cell types evaluated included:
Mesangial matrix 0  Normal mesangium
peritubular (interstitial) capillary endothelial cells (the 1  Mild expansion
2  Moderate expansionprimary endpoint of the Phase 3 trial), glomerular endo-
a For the podocytes and distal convoluted tubules (DCT)/collecting ducts, anthelial cells, mesangial cells, arterial/arteriolar endo-
increase (), a decrease () or no change (0) response was collected for allthelial cells, vascular smooth muscle cells, interstitial cells post-baseline scores by comparing the baseline biopsy to a 5 or 11 month biopsy.
Therefore, there are no absolute baseline values for these cell types, only relative(a mixed cell population of fibroblasts and phagocytic
values at 5 months and 11 months that reflect a comparison to the baseline.cells), podocytes, and the epithelium of distal convoluted
tubules and collecting ducts. The mesangial cell matrix
of individual glomeruli was also evaluated for pathologic
change. Scoring of these elements was conducted accord-
Immunofluorescenceing to the design shown in Table 1. For each cell type
listed, a majority score (the score common to at least 2 Immunofluorescence studies also were performed to
of the 3 evaluating pathologists) was derived from the determine whether IgG antibodies against r-hGalA,
individual scores of the three pathologists. When there which developed in most patients receiving the enzyme,
was no common score for the primary endpoint (peritu- had resulted in immune complex deposition in the kidney.
bular endothelial cells), the pathologists were recon- Frozen tissue samples from five r-hGalA-treated patients
vened for an adjudication. They reviewed the slide to- who developed IgG antibodies by the five month biopsy
gether at a multi-headed scope to reach a consensus (IgGGroup), three r-hGalA–treated patients who did
score. For other cell types, the median score was selected. not develop IgG antibodies at five months (IgGGroup),
The distribution of these scores is summarized in Fig- and five untreated placebo patients (Control Group) were
ure 1 and Table 2. Figure 1 shows the distribution of analyzed. Pre-treatment, baseline samples were available
the means of all scores available at each time point. Ta- from two of these patients (one IgG and one IgG).
ble 2 shows the distribution of the score shifts from base- Four-micron sections from fresh frozen blocks of renal
line. The differences in the “N” values between these biopsies were stained with IgG fractions of fluorescein-
two images are due to different presentation of the data. conjugated monospecific antisera to human IgG, IgA,
In some instances, certain cell types were absent from IgM, C3, C1q, fibrin/fibrinogen, and albumin (Dako
individual biopsy samples, and could not be evaluated Corp., Carpinteria, CA, USA) by standard clinical tech-
at all time points. To allow for the variation occurring niques [20]. Frozen sections were cut in a cryostat at
among glomeruli, the mesangial cell matrix for each indi- 20C and placed on Fisher Superfrost Plus slides (Fisher
vidual glomerulus in the biopsy samples (to a maximum Scientific) and then air-dried. Using a Tissue-Tek II slide
of 8) received a score ranging from 0 to 2. Individual staining unit, slides were placed on a clinical rotator
glomerular scores were then averaged for each pathol- and pre-washed for five minutes in 0.01 mol/L sodium-
ogist. The mean for the three pathologists’ scores was phosphate-buffered saline (PBS), 0.15 mol/L NaCl, pH
then calculated. 7.3. One drop (50 to 100L) of diluted fluorescein conju-
gate was applied to the tissue section. The optimal con-
Electron microscopy centration for each conjugate was determined by titering
on known positive and negative control tissues. SlidesThin sections were cut from the tissue blocks prepared
above and stained with 5% uranyl acetate (in a 1:1 mix- were then incubated in a moist, level, covered chamber
for 30 minutes at room temperature. After incubation,ture, methanol:water) and a modified Reynold’s Lead
Citrate. Photographs were taken at 3300 and 10,000 the slides were washed in PBS for five minutes  4. The
excess PBS was blotted from around the specimen, andmagnification using a JEM 100CX electron microscope
(JEOL, Ltd, Tokyo, Japan). the moistened tissue was coverslipped with Aquamount
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Fig. 1. Mean globotriaosylceramide (GL-3) scores with standard deviations were calculated for each cell type above in both the treatment
groups at baseline, 5 months and 11 months. Note the rapid decline in mean GL-3 scores for the placebo group once enzyme replacement therapy
was initiated after the 5-month time point. Treatment groups maintained their low GL-3 scores from the pivotal study (baseline to 5 months) into
the extension segment of the study (evaluated at 11 months). (A) Peritubular capillary endothelial cells; (B) glomerular capillary endothelial cells;
(C ) arterial/arteriolar endothelial cells; (D) vascular smooth muscle cells; (E ) mesangial cells; (F ) interstitial cells. (Note: The differences in the
“N” values between Figure 1 and Table 2 are due to different presentation of the data. In some instances, certain cell types were absent from individual
biopsy samples, and could not be evaluated at all time points. Hence, the shift data presented in Table 2 have lower “N” values in some cases.)
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Table 2A. Percentage of patients achieving zero scores*
(percentages of patients with a 1–3 point score reduction, including all zero scores, are shown in parentheses)
Score shift from baseline to 5 months Score shift from baseline to 11 months
Renal cells evaluated TX group Baseline 5 months N Baseline 11 monthsa N
Peritubular capillary endothelial cells Placebo 0% 0% (38%) 29 0% 100% (100%) 24
A-gal 3% 69% (86%) 29 0% 92% (96%) 25
Glomerular capillary endothelial cells Placebo 0% 0% (31%) 16 0% 100% (100%) 21
A-gal 0% 100% (100%) 19 0% 100% (100%) 17
Mesangial cells Placebo 0% 0% (19%) 16 0% 90% (100%) 21
A-gal 0% 100% (100%) 19 0% 100% (100%) 17
Interstitial cells Placebo 0% 0% (0%) 24 0% 78% (91%) 24
A-gal 4% 71% (100%) 24 4% 100% (100%) 24
Arterial/arteriolar endothelial cells Placebo 0% 0% (19%) 22 0% 87% (100%) 22
A-gal 10% 86% (100%) 21 9% 96% (100%) 22
Vascular smooth muscle cells Placebo 0% 0% (10%) 22 0% 0% (86%) 22
A-gal 0% 10% (86%) 21 0% 0% (81%) 21
* The clearance of GL-3 from multiple renal cell types was determined before and after enzyme replacement therapy. There were two groups of patients: (1 ) the
placebo group received placebo for the first 5 months and then -galactosidase A for the remaining 6 months and (2 ) the A-gal group which received -galactosidase A
for the entire 11 months. The percentage of patients who attained a zero score at each biopsy time point is displayed and the percentage of all patients who
demonstrated a reduction in score, including all zeros, is in parentheses. Values are presented for both the placebo and treatment groups. For statistical purposes,
it was necessary for each patient to have both a baseline score and a shift score (5 months or 11 months) for each cell type, in order to be included in this data set.
Two baseline columns are presented; the “N” designates the number of paired scores available for each cell type (paired scores meaning baseline and 5 months, or
baseline and 11 months). This permitted calculation of the statistical significance of the change in score from either baseline to 5 months, or from baseline to 11
months, when comparing the placebo and treated groups. This distinction was necessary because (1 ) some patients had a poorly preserved or missed biopsy at one
of the time points, and (2) some biopsy specimens did not contain glomeruli and therefore those cells could not be evaluated at all time points.
Table 2B. Percentage of patients achieving a reduction in GL-3 relative to baseline*
5 months 11 monthsa
TX group % N % N
Tubular epithelium Placebo 4% 24 78% 24
A-gal 25% 24 50% 24
Podocytes Placebo 0% 16 23% 22
A-gal 5% 19 18% 17
* Tubular epithelium and podocyte clearance were expressed as the percentage of patients attaining a relative reduction in the 5 month and 11 month biopsy. An
increase (), a decrease () or no change (0) response was collected for all post baseline scores by comparing the baseline biopsy to a 5 or 11 month biopsy. Therefore,
there are no absolute baseline values for these cell types, only relative values at 5 months and 11 months that reflect a comparison to the baseline. A-gal represents
patients treated with the recombinant human enzyme, -galactosidase A.
a Placebo group has crossed over to treatment at this time point
nuclear cytoplasmic inclusions. GL-3 also accumulatedand glycerol (Lerner Labs, Pittsburgh, PA, USA). Coded
in severely affected cells as larger grouped inclusions inslides were scored blinded, without knowledge of treat-
the peripheral cytoplasm. The larger cytoplasmic inclu-ment groups or antibody status, using an epi-illumination
sions often clustered and protruded into the lumens offluorescence microscope. The intensity and distribution
small capillaries (Figs. 3A and 4A). On electron micros-of glomerular staining was scored from 0 to 4 for each
copy many of these granules were dense and amorphousof the antibodies.
(Fig. 3C). Vascular smooth muscle cells also accumulated
moderate amounts of granular, cytoplasmic GL-3 (Fig.
RESULTS 5A). GL-3 in mesangial cells appeared as dense granules
Baseline biopsies clustered around the nucleus in the cytoplasm (Fig. 6A).
Interstitial fibroblasts and phagocytic cells (“interstitialAt baseline, GL-3 accumulation in the kidney tissues
cells”) of the renal cortex also shared a similar appear-was extensive, but varied considerably in quantity and
ance (Fig. 7A).morphology among the different cell types (Fig. 2). Po-
Lipid accumulation in podocytes and the epithelial cellsdocytes and distal tubular epithelial cells contained the
of distal convoluted tubules and collecting ducts washighest concentrations of GL-3 inclusions, whereas prox-
much more concentrated and extensive than the accumu-imal tubular epithelial cells were relatively unaffected.
lation present in endothelial cells, smooth muscle cells,The appearance of the lipid inclusions also varied, appear-
mesangial cells or interstitial cells. Podocyte nuclei wereing in some cell types as small, dark, dense beaded gran-
often eccentrically positioned, pushed aside by the massules, and in others as larger, complex, laminated bodies
of accumulated GL-3 inclusions in the form of multiple(myelin figures).
scroll-like myelin figures filling the entire cytoplasm (Fig.Globotriaosylceramide accumulation in vascular en-
dothelial cells appeared as small, dense, beaded, peri- 8A). The laminated appearance was particularly promi-
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Fig. 2. GL-3 accumulates as dark blue gran-
ules and scroll-like whorls in multiple cell types
of the renal glomerulus. Red arrows indicate
endothelial accumulation; yellow arrows indi-
cate mesangial cell accumulation; green “P”
indicates podocyte accumulation (Magnifica-
tion, 40 objective).
Fig. 3. GL-3 is cleared from endothelial cells of the peritubular (inter-
stitial) capillaries. (A) Baseline biopsy, pre-treatment. GL-3 is present
near endothelial nuclei and around the perimeter of the capillaries. (B)
Post-treatment biopsy. Capillaries are clear of GL-3 (magnification of
A and B, 100 objective). (C ) Electron microscopic image of capillary
endothelial cell GL-3 accumulations (arrows) protruding into the lumen,
at baseline (Magnification, 3300).
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Fig. 4. GL-3 is cleared from endothelial cells
of the glomerular capillaries. (A) Baseline bi-
opsy, pre-treatment. Note how large clusters
of GL-3 granules protrude into the vascular
lumens of the glomerular capillaries. (B) Post-
treatment biopsy. Protruding GL-3 clusters have
been completely removed from the glomeru-
lar capillary lumens (magnification, 100 ob-
jective).
Fig. 5. GL-3 is cleared from endothelial cells
(black arrows) and smooth muscle cells (red
arrows) of renal arterioles. (A) Baseline bi-
opsy, pre-treatment. Note how GL-3 accumu-
lates in very large clusters in endothelial cells
of these larger vessels. (B) Post-treatment bi-
opsy. Both endothelial cells and smooth mus-
cle cells of this vessel have achieved significant
clearance of GL-3 (magnification, 100 ob-
jective).
Fig. 6. GL-3 is cleared from mesangial cells.
(A) Baseline biopsy, pre-treatment. Dense
GL-3 granules accumulate around the nuclei
of mesangial cells. (B) Post-treatment. Mesan-
gial cells are completely cleared of GL-3 (mag-
nification, 100 objective).
Fig. 7. GL-3 is cleared from interstitial cells.
(A) Baseline biopsy, pre-treatment. GL-3 fills
most of the cytoplasm of these interstitial cells.
(B) Post-treatment. The interstitial cell cyto-
plasm has been cleared of GL-3 (magnifica-
tion, 100 objective).
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Fig. 8. GL-3 is cleared from podocytes. (A) Baseline biopsy, pre-treatment. GL-3 appears as multiple, tight scroll-like figures that fill the cytoplasm
of each podocyte. (B) Post-treatment. The scroll-like GL-3 forms are looser and less numerous after treatment. Podocytes are outlined pre- and
post-treatment for emphasis (magnification of A and B, 100 objective). (C ) Electron microscopic image demonstrating the lamellar ultrastructure
of the GL-3 accumulation in podocyte cytoplasm at baseline (magnification, 10,000).
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Fig. 9. GL-3 is cleared from tubular epithelium.
(A) Baseline biopsy, pre-treatment. GL-3 ap-
pears as multiple small and large dense granules,
some with a scroll-like architecture, within the
epithelial cell cytoplasm of distal convoluted
tubules and collecting ducts. (B) Post-treat-
ment. The granules are fewer in number after
treatment (magnification, 100 objective).
nent by electron microscopy (Fig. 8C). GL-3 accumula- cebo-controlled (5 month) study (P 	 0.001; based on
a 
2 test). After crossover to treatment for an additionaltions in the epithelium of distal convoluted tubules and
collecting ducts were similar in concentration and ap- six months, 100% (Table 2A) of the former placebo
patients achieved an endothelial score of zero at monthpearance to those in the podocytes (Fig. 9A).
11, demonstrating complete clearance (P 	 0.001).
Post-treatment biopsies For glomerular capillary endothelial cells, patients re-
ceiving r-hGalA from baseline to five months demon-Vascular endothelium. Treatment with r-hGalA re-
strated 100% clearance of GL-3 (Fig. 4B), all attainingsulted in statistically significant clearance of lipid from
endothelial scores of zero (baseline mean  2.5; five-endothelial cells of all vessel types examined: peritubular
month post-treatment mean  0.0; Fig. 1B). All patientscapillaries, glomerular capillaries and arterial/arteriolar
in this treatment group maintained a score of zero (com-vessels.
plete clearance) after an additional six months of treat-In the patient group receiving r-hGalA from baseline
ment. In the placebo group, 0% of patients attained zeroto five months, 86% demonstrated a reduction (or main-
endothelial scores from baseline to five months (baselinetained a zero score) in GL-3 from peritubular capillary
mean  2.6; five-month post-placebo mean  2.4; Fig.endothelial cells (Fig. 3B); 69% of patients achieved an
1B). There was a statistically significant difference be-endothelial score of zero (baseline mean  1.9; five-
tween the r-hGalA and placebo treated patients in themonth post-treatment mean  0.3; Fig. 1A). After an ad-
placebo-controlled (5 month) study (P 	 0.001). Afterditional six months of treatment, 96% of patients in
this treatment group demonstrated a reduction in score crossover to treatment for an additional six months, how-
ever, 100% of the former placebo patients achieved en-(relative to baseline), with 92% achieving a score of
zero (complete clearance), as demonstrated by biopsy at dothelial scores of zero at month 11, demonstrating com-
plete clearance (P 	 0.001).month 11. In the placebo group, 38% of patients demon-
strated a reduction in GL-3 from baseline to five months; Examination of the arterial/arteriolar endothelial cells
demonstrated that 100% of the rh-GalA–treated pa-however, none (0%) achieved a score of zero (baseline
mean  2.2; five-month post-placebo mean  2.1; Fig. tients had reduced GL-3 levels (Fig. 5B), with 86% achiev-
ing a score of zero from baseline to five months (baseline1A). There was a statistically significant difference be-
tween r-hGalA and placebo-treated patients in the pla- mean  2.5; five-month post-treatment mean  0.1; Fig.
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1C). After an additional six months of treatment, these had moderate mesangial matrix widening (r-hGalA–
treated group, mean score  0.8; placebo group, meanpatients continued to improve, with 96% achieving a score
of zero for complete clearance. In the placebo group, 19% score  0.9). There was no statistically significant differ-
ence between the mean scores from baseline to five monthsof patients demonstrated a reduction in GL-3 score, how-
ever, none received a score of zero from baseline to five for the amount of matrix in either treatment group (P 
0.284). Change from baseline to 11 months showed amonths (baseline mean  3.0; five-month post-placebo
mean 2.8; Fig. 1C). There was a statistically significant mean score decrease of only 0.1 for patients treated with
the enzyme for the entire 11 months.difference in the percentage of zero scores between
treated and placebo groups in the placebo-controlled Interstitial cells. The lipid in interstitial cells was
cleared after five months of treatment in the majority ofstudy (P	 0.001). After the crossover to enzyme therapy
for six months, 100% of the former placebo patients dem- patients (Fig. 7B). In the r-hGalA cohort from baseline
to five months, 100% demonstrated a reduction (or main-onstrated a reduction in GL-3 score with 87% achieving
zero scores (P 	 0.001; Table 2A). tained zero scores) in GL-3 score, with 71% achieving
complete clearance of interstitial cell GL-3 (baselineVascular smooth muscle cells. Enzyme therapy re-
moved GL-3 from vascular smooth muscle cells (Fig. mean  1.8; five-month post-treatment mean  0.3; Fig.
1F). After an additional six months of treatment, 100%5B), although the clearance was less complete than that
observed in other cell types. In the patient group treated of the treatment group had achieved zero scores. In the
placebo group, 0% achieved zero scores from baselinewith r-hGalA from baseline to five months, 86% dem-
onstrated a reduction in GL-3 score; however, only 10% to five months (baseline mean  1.9; five month post-
placebo mean  2.0; Fig. 1F). There was a statisticallyreceived zero scores (baseline mean  2.7; five-month
post-treatment mean 1.6; Fig. 1D). After an additional significant difference in the percentage of zero scores
between treated and placebo patients in the placebo-six months of treatment these values were relatively un-
changed, as 81% demonstrated a reduction in GL-3 score controlled study (P 	 0.001). After crossover to treat-
ment for six months, 91% of the former placebo groupand 0% had a score of zero. At this time point, reversal
of zero scores occurred in two patients: one received a demonstrated a reduction in GL-3 score, with 78% (Ta-
ble 2A) achieving a score of zero (P 	 0.001).score of 1 and the other received a score of 2. In the
placebo group, 10% of patients demonstrated a reduc- Epithelial cells: Podocytes and tubular epithelium. Po-
docytes responded to r-hGalA enzyme therapy withtion in GL-3 score, however, none achieved a score of zero
(baseline mean  3.0; five-month post-placebo mean  a modest reduction in the numbers of lamellar GL-3
inclusions (Table 2B), and in many cases a more varied2.9; Fig. 1D). After crossover to treatment with r-hGalA
for an additional six months, 86% (Table 2A) demon- cytoplasmic GL-3 morphology, with some myelin figures
being reduced to loose scroll-shaped bodies floating instrated a reduction in GL-3 score and the mean score
declined to 1.8 (Fig. 1D). the cell cytoplasm (Fig. 8B). In the r-hGalA treated
group, 5% showed a reduction in podocyte GL-3 afterMesangial cells. The lipid inclusions in mesangial cells
of the renal glomeruli were cleared after five months of five months. This increased to 18% after an additional
six months of treatment, demonstrating continued im-enzyme treatment (Fig. 6B). Scored on a scale from 0
to 2, the mesangial cells of all patients (100%) treated provement of GL-3 clearance. In the placebo group, 0%
of patients showed a reduction in GL-3 accumulationwith rh-GalA from baseline to five months demon-
strated complete clearance (zero scores) of GL-3, and from baseline to five months. After crossover to treatment
for an additional six months, 23% of patients began tomaintained their zero scores after an additional six months
of r-hGalA (baseline mean 1.8; 5 and 11 month post- show a relative reduction in podocyte GL-3 (Table 2B).
For the tubular epithelium, 25% of the samples in thetreatment means  0.0; Fig. 1E). In the placebo group,
19% of patients showed a reduction in GL-3 scores, r-hGalA-treated group from baseline to five months
demonstrated a relative reduction in GL-3 accumulation.however, none achieved a score of zero from baseline
to five months (baseline mean  2.0; five month post- After an additional six months of treatment in the exten-
sion study, 50% of these patients demonstrated a reduc-placebo mean  1.8; Fig. 1E). There was a statistically
significant difference in the percentage of zero scores tion in GL-3 (Fig. 9B). In the placebo group, only 4%
demonstrated a reduction in GL-3 from baseline to fivebetween treated and placebo patients during the pla-
cebo-controlled study (P 	 0.001). After crossover to months; however, after crossover to r-hGalA treatment
for an additional six months, 78% of patients in thistreatment for an additional six months, 100% of the
former placebo patients achieved a reduction in GL-3, group demonstrated a relative reduction in tubular epi-
thelium GL-3 (Table 2B).with 90% (Table 2A) receiving a zero score indicating
complete clearance of glycosphingolipid from the mesan- Immunofluorescence for immune complex deposition.
None of the patient samples tested (5 anti-r-hGalA IgGgial cells (P 	 0.001).
Mesangial cell matrix. At baseline, both treatment groups positive, 3 anti-r-hGalA IgG negative, 5 placebo, and
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Table 3. Immunofluorescence result on glomerular deposits
IgG IgA IgM C3 C1q Fibrin/fibrogen
IgG
Biopsy # anti-rhGAL GBM Mes GBM Mes GBM Mes GBM Mes GBM Mes GBM Mes
Treated, with IgG titers titer
349 25600 0 0 0 0 0 0.5 0 0.5 0 0 0 0
359 25600 0.5 0 0.5 0.5 2 0.5 3 1 0 0.5 2 0
463 12800 0 0 0 0 0 0.5 0 0.5 0 0 0 0
73 12800 0 0 0 0 0 0.5 0 0.5 0 0 0 0
207 12800–25600 0 0 2 1 2 0.5 0 0.5 0 0 0 0.5
207 Pre pre-treatment 0 0 0.5 1 2 1 0 0.5 0 0 0 0.5
Placebo with no IgG titers
323 0 0 0.5 0.5 0 0.5 0 0.5 0 0 2 0.5
118 0 0 0 0 0 0.5 0 0.5 0 0 0.5 0.5
127 0 0 0.5 0.5 0 0.5 0 0.5 0 0 0.5 0.5
103 0 0 0 0 3 0.5 0 0.5 0 0 0.5 0.5
289 0 0 0 0 2 1 0 0.5 0 0 0 0.5
Treated, no IgG titers
232 0 0 0 0 0.5 0.5 0.5 0.5 0 0 0 0
52 0 0 0 0 0.5 1 0 0.5 0 0 0.5 0.5
23 0 0 2 2 0.5 0 0.5 0.5 0 0 2 0.5
23 Pre pre-treatment 0 0 1 2 2 1 0 0 0 0 0 0.5
Summary table of immunofluorescence results on immune complex deposition in the glomeruli of Fabry patients on Fabrazyme. Abbreviations are: GBM,
glomerular basement membrane; Mes, mesangium. The intensity and distribution of glomerular staining were scored from 0 to 4 for each of the parameters listed.
Note that IgG staining was negligible in all specimens examined for immune complex disease.
2 pre-treatment samples) had more than trace deposits of cell types, such as endothelial cells, containing smaller
IgG in their glomeruli detected by immunofluorescence glycolipid inclusions.
(Table 3). Two patients had IgA deposition, suggestive Variation in the amount of accumulated GL-3 among
of IgA nephropathy (one in the IgG positive group and cells deficient in r-hGalA is presumably determined by
one in the IgG negative group). Pre-treatment samples the amount of substrate generated by the cell type in
were available for each of these patients and showed question and the rate of cell turnover. The rate at which
pre-existing IgA deposits. Three others had segmental substrate is cleared will be determined by these same
IgM deposits typical of focal sclerosis (one IgG positive factors, plus the degree of exposure of the cell to the
and two IgG negative patients). These findings indicate administered replacement enzyme. The ability of the en-
that despite five months of r-hGalA treatment, patients zyme to pass through various cellular and acellular barri-
with plasma IgG antibodies against the enzyme had no ers, such as the glomerular filtration apparatus, will de-
evidence of immune complex deposition in their kidneys. termine its effectiveness at clearing substrate in different
cell types. Fabrazyme (r-hGalA) is a 110 kD dimeric
glycoprotein containing mannose-6-phosphate terminatedDISCUSSION
carbohydrates. It has been designed to target the cation-The quantity of GL-3 that accumulates in different
independent mannose-6-phosphate receptor (CIMPR),cell types in Fabry disease varies considerably. Some
a receptor present on all normal mammalian cells. Thecells such as keratinocytes, proximal tubular epithelium
CIMPR cycles continuously from the cell surface whereand liver parenchyma are relatively devoid of lysosomal
it binds and endocytoses mannose-6-phosphate-con-inclusions, whereas cardiomyocytes, podocytes and distal
taining ligands (such as newly synthesized lysosomal en-tubular epithelial cells are heavily laden. This cell-to-cell
zymes that have escaped sorting in the Golgi) to thevariation also is reflected in the total glycolipid content
lysosome, where these ligands are released [21, 22].of different organs, in which certain cell types dominate.
Of the renal cell types examined in this study, endothe-In the Phase I/II trial, mean whole tissue concentrations
lial cells turn over the most frequently [23, 24] and, asof GL-3 were 21,400 ng/mg in the heart, 5530 ng/mg in
demonstrated for the three vessel types examined (peri-the kidney, 350 ng/mg in the skin and 1948 ng/mg in the
tubular capillaries, glomerular capillaries, and arteriolesliver [9]. The extremely high level in the heart reflects
and small arteries), were cleared of GL-3 within fivethe predominance of the heavily laden cardiomyocytes
months of initiating enzyme replacement treatment. Fur-in heart tissue, whereas the relatively low level in the
thermore, as a consequence of intravenous delivery, theliver reflects the dominance of parenchymal cells that
mannose-6-phosphate receptors on the surface of endo-were relatively free of GL-3. The kidney falls in the
thelial cells are likely to be exposed to the highest con-intermediate range since heavily laden cells such as po-
docytes and distal tubular epithelium are mixed with centration of delivered enzyme. Thus, during the limited
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50 to 100 day lifespan of endothelial cells [23], only a concentrated along the distal convoluted tubules and
collecting ducts. Therefore, it is probable that the epithe-modest amount of GL-3 accumulates before the cell is
replaced. The combination of rapid cell turnover and lia of the distal convoluted tubules and collecting ducts
are exposed to high concentrations of GL-3, leading tomaximum exposure to r-hGalA most likely explains
the high degree of success in removing GL-3 from this active or passive uptake. This may explain the marked
accumulation of GL-3 observed in both this transplantedkey tissue within the first five months of treatment.
Mesangial cells also have a relatively rapid turnover kidney and in the kidneys of all Fabry patients.
The similarities in the pattern and appearance of GL-3rate [23] and demonstrated near complete GL-3 clear-
ance within five months of initiating enzyme replacement accumulation in glomerular and tubular epithelia, de-
spite their widely differing functions, are most likely atherapy. The path of exposure of mesangial cells to
r-hGalA is unclear since the glomerular filtration bar- reflection of their common embryonic origin. The large
quantity and organized ultrastructure of GL-3 in highlyrier normally traps molecules greater that 69 kD. How-
ever, since the mesangial cells are in the immediate laminated myelin bodies in podocytes also is consistent
with a lifetime of GL-3 accumulation due to untreatedplasma filtration pathway of injured glomerular endothe-
lium, which may allow passage of protein, mesangial cells disease. Indeed, GL-3 accumulation has been observed in
the renal epithelial cells of second trimester, hemizygousare likely to have relatively high exposure to the enzyme.
Immunohistochemical detection of the CIMPR on Fabry fetuses [28, 29], indicating early and active accumulation
in these cells. Similar high concentrations of large, highlyrenal tissue has demonstrated that mesangial cells, as
well as other affected renal cells, are rich in the receptor structured lysosomal inclusions are seen in cardiomyo-
cytes, cells that are terminally differentiated with no(Genzyme; unpublished observations). The interstitial
cells accumulated small, dense GL-3 granules similar to regenerative capacity [30]. Given the large quantity of
GL-3 in the renal epithelial cells, it is likely that imple-those seen in endothelial and mesangial cells, and re-
sponded to enzyme replacement therapy to a similar mentation of enzyme replacement therapy over an ex-
tended period will be required to effect complete clear-degree. The interstitial cell population is comprised of
fibroblast-like and phagocytic cells dispersed through- ance. Since these cells are further down the filtration
pathway they may suffer from less exposure to intrave-out the extra-glomerular interstitium. While there is lit-
tle information on the turnover rate of this cell popula- nously delivered enzyme. Nonetheless, there was good
evidence from histologic examination of the podocytestion, the rapid clearance of GL-3 observed suggests that
regular cell turnover may play a role in the response of and distal tubular epithelial cells that r-hGalA had re-
duced the high baseline levels of GL-3 in these cells.these cells.
The parietal epithelial cells (Bowman’s capsule), fol- Numerous case reports suggest that while damage to
podocytes, which play a role in the filtration of plasmalowed by the visceral epithelial cells (podocytes) have
the slowest turnover rate of the renal cell populations proteins, may explain the presence of proteinuria in both
hemizygotes and heterozygotes, this aspect alone cannot[23–25]. The tubular epithelium, however, is regularly
shed in the urine and replaced, and has been shown to account for the precipitous renal failure in hemizygous
male patients. Although the accumulation of GL-3 inhave a relatively high proliferation index [24]. This may
account for the faster rate of GL-3 clearance following podocytes of Fabry patients is dramatic, the renal pathol-
ogy of some asymptomatic heterozygous females is ofteninitiation of enzyme replacement therapy compared to
that of podocytes. However, despite its high proliferation limited to significant accumulations of GL-3 in the podo-
cytes with little alteration in renal function [1–3, 31].index, the tubular epithelium is more heavily laden with
GL-3 than one might at first expect for a cell population One case report describes the inadvertent use of a het-
erozygous Fabry donor for transplantation to a geneti-that is regularly shed. Reports on the re-accumulation of
GL-3 in normal kidneys transplanted into Fabry patients cally normal recipient. The graft was later found to con-
tain numerous epithelial cell inclusions, but continuedprovide some insight into this apparent contradiction.
One autopsy case reports the recurrence of Fabry disease to function normally for 20 years [32, 33]. There is also
a report of a 28-year-old male hemizygote with a sub-in a transplanted kidney 11 years after transplant. Exami-
nation of the renal allograft revealed isolated accumula- clinical variant of Fabry disease whose only renal pathol-
ogy was podocyte accumulation of GL-3 [34]. This pa-tion of GL-3 in the endothelial cells of the capillaries [26].
It was suggested that high circulating levels of plasma tient had a partial deficiency of -galactosidase A. This
finding suggests that while his enzyme level was not suf-GL-3 may overwhelm the enzymatic capacity of endothe-
lial cells, which may accumulate GL-3 from the plasma by ficient to prevent podocyte accumulation, it was enough
to prevent clinical disease as seen in female heterozy-passive or endocytotic mechanisms. More importantly, a
second autopsy case reported accumulation of GL-3 in gotes. These cases and others [19, 35–39] suggest that re-
sidual enzyme activity, while perhaps not eliminatingboth capillary endothelial cells and tubular epithelial cells
in a renal allograft 14 years after transplant [27]. Urine is all signs of clinical or histologic disease, is still able to
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significantly extend the patient’s lifespan by obviating apy. As mentioned earlier, complete clearance of a life-
renal failure. time accumulation of GL-3 from some cell populations,
Most of the patients in the Genzyme-sponsored Phase such as cardiomyocytes and podocytes, is likely to require
III trial developed circulating IgG antibodies to r-hGalA an extended treatment period. The most benefit would
by the 3rd to 7th dose of enzyme [10]. However, the efficacy be afforded to those who begin treatment early in life,
of r-hGalA was not impaired by antibody development. with the aim of arresting GL-3 cellular accumulation at
This determination is based on the continued reduction sub-clinical levels. Residual enzyme activity in the cases
in histologic scores for cellular clearance of GL-3 through described appears to maintain clearance of GL-3 from
the Extension study, even in patients who developed tran- vascular endothelial cells and prevents the thrombosis-
siently higher titers [10]. As a safety measure, we also related injuries contributing to early morbidity and pre-
sought evidence of immune complex deposition in the mature mortality in classical Fabry patients.
kidney by immunofluorescence. Despite antibody titers Clearance of GL-3 accumulation from cell types other
of 12,800 units in the five r-hGalA-treated patients than the vascular endothelium is likely to have consider-
tested, no IgG deposits were found in their glomeruli. able benefit for the overall health of the kidney by com-
Segmental IgM was occasionally present, as expected in plementing the anti-inflammatory and anti-thrombotic
lesions with segmental scars, and was not correlated with benefits of vascular endothelial clearance. The mesan-
anti-r-hGalA antibodies. IgA deposition was detected gium, composed of cells and matrix, provides support to
in two treated patients (one with anti-r-hGalA antibod- the glomerular capillary tuft. Mesangial cells have con-
ies and one without). Similar IgA deposits were present tractile properties that mediate filtration, and phagocytic
in the pre-treatment biopsies of each patient, indicating properties that clean debris from the mesangium. Injury
that the process pre-dated r-hGalA exposure. to mesangial cells primarily from intracellular GL-3 accu-
Recent evidence that the endothelium of Fabry patients mulation, and secondarily from capillary tuft vascular
is in a pro-inflammatory and pro-thrombotic state [11, 13] impairment, leads to the proliferation of cells and matrix,
supports the predominant role of vascular pathology in which in turn contributes to glomerulosclerosis [11]. Dur-
the pathogenesis of Fabry disease, including kidney fail- ing this study, we observed complete removal of GL-3
ure [18]. Further evidence for the primary importance from mesangial cells and no change in mesangial cell
of the endothelial cells in the pathophysiology of Fabry matrix deposition. This observation may indicate either
disease comes from a comparison of the cardiac variant that treated mesangial cells cease or stabilize in their
of Fabry disease with the classical form. Cardiac variant secretion of matrix, or that the deposition of matrix in
patients have marked GL-3 accumulation in cardiomyo- Fabry disease is too slow to observe appreciable changes
cytes, renal tubular epithelium and podocytes, as is seen during an 11-month period.
also in classical Fabry patients, yet cardiac variants dem- The long-term treatment goal for Fabry patients is
onstrate little to no endothelial accumulation of GL-3. ultimately to prevent significant kidney pathology from
This difference suggests that the extended lifespan en- developing by providing enzyme replacement therapy
joyed by cardiac variant patients (relative to the short- early in life. For older patients, the goal is to halt the
ened lifespan of classical Fabry patients) may be due to progression of existing kidney pathology before the
their lack of endothelial GL-3 accumulation. Male car- threshold of renal reserve is reached and life-threatening
diac variants have residual enzyme activity, and this may renal failure ensues. Given the effectiveness of r-hGalA
be sufficient to keep endothelial cells clear of GL-3, in clearing GL-3 from all of the relevant cell types of
thereby delaying the renal disease usually responsible the kidney, even if slowly in podocytes and distal tubular
for the death of the classical Fabry patient. The extended epithelial cells, slowing the progression of disease in pa-
lifespan of the cardiac variant patient provides time for tients with early signs of renal failure also may be realis-
the GL-3 accumulation in the heart muscle to manifest tic. This pathology study has demonstrated that enzyme
itself clinically, as these patients often die later in life therapy with r-hGalA resulted in significant clearance
of cardiac disease [40]. Published case reports illustrate of the accumulated substrate from not only the critical
these points. The autopsy of a 63-year-old cardiac variant endothelial compartment, but from all of the cell types
who died of conduction system abnormalities caused by involved in the renal pathology of Fabry disease, thereby
glycosphingolipid accumulation, also was found to have providing a realistic means of stabilizing the disease and
GL-3 restricted to renal epithelial cells [41]. Clinically, avoiding progression to clinical failure.
the patient’s renal decline was likely delayed by the resid-
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